EGR1 Antibody - #AF0589

(3)   (8)  
Product: EGR1 Antibody
Catalog: AF0589
Description: Rabbit polyclonal antibody to EGR1
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Monkey
Mol.Wt.: 56kDa; 58kD(Calculated).
Uniprot: P18146
RRID: AB_2834263

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Monkey
Clonality:
Polyclonal
Specificity:
EGR1 Antibody detects endogenous levels of total EGR1.
RRID:
AB_2834263
Cite Format: Affinity Biosciences Cat# AF0589, RRID:AB_2834263.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AT225;Early growth response 1;Early growth response protein 1;EGR 1;EGR-1;EGR1;EGR1_HUMAN;G0S30;KROX 24;KROX24;Nerve growth factor-induced clone A;Nerve growth factor-induced protein A;NGFI-A;NGFIA;TIS8;Transcription factor ETR103;Transcription factor Zif268;ZIF 268;ZIF268;Zinc finger protein 225;Zinc finger protein Krox-24;ZNF225;

Immunogens

Immunogen:

A synthesized peptide derived from human EGR1, corresponding to a region within the internal amino acids.

Uniprot:

P18146(EGR1_HUMAN) >>Visit HPA database.

Gene(ID):
EGR1(1958)
Expression:
P18146 EGR1_HUMAN:

Detected in neutrophils (at protein level).

Description:
NAB2 acts as a transcriptional repressor for zinc finger transcription factors EGR1 and EGR2. Isoform 2 lacks repression ability (By similarity).
Sequence:
MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC

PTMs - P18146 As Substrate

Site PTM Type Enzyme
S12 Phosphorylation
S26 Phosphorylation
S104 Phosphorylation
S120 O-Glycosylation
T148 Phosphorylation
S196 Phosphorylation
S301 Phosphorylation
K317 Acetylation
S378 Phosphorylation P68400 (CSNK2A1)
T389 Phosphorylation
T391 Phosphorylation P68400 (CSNK2A1)
T526 Phosphorylation P68400 (CSNK2A1)

Research Backgrounds

Function:

Transcriptional regulator. Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'(EGR-site) in the promoter region of target genes (By similarity). Binds double-stranded target DNA, irrespective of the cytosine methylation status. Regulates the transcription of numerous target genes, and thereby plays an important role in regulating the response to growth factors, DNA damage, and ischemia. Plays a role in the regulation of cell survival, proliferation and cell death. Activates expression of p53/TP53 and TGFB1, and thereby helps prevent tumor formation. Required for normal progress through mitosis and normal proliferation of hepatocytes after partial hepatectomy. Mediates responses to ischemia and hypoxia; regulates the expression of proteins such as IL1B and CXCL2 that are involved in inflammatory processes and development of tissue damage after ischemia. Regulates biosynthesis of luteinizing hormone (LHB) in the pituitary (By similarity). Regulates the amplitude of the expression rhythms of clock genes: ARNTL/BMAL1, PER2 and NR1D1 in the liver via the activation of PER1 (clock repressor) transcription. Regulates the rhythmic expression of core-clock gene ARNTL/BMAL1 in the suprachiasmatic nucleus (SCN) (By similarity).

Subcellular Location:

Nucleus. Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in neutrophils (at protein level).

Subunit Structure:

Interacts with SNAI1 and SP1 upon 12-O-tetradecanoylphorbol-13-acetate (TPA) induction.

Family&Domains:

Binds to DNA motifs with the sequence 5'-GCG(T/G)GGGCG-3' via its C2H2-type zinc fingers (PubMed:25258363, PubMed:25999311). The first, most N-terminal zinc finger binds to the 3'-GCG motif, the middle zinc finger interacts with the central TGG motif, and the C-terminal zinc finger binds to the 5'-GCG motif. Binds double-stranded target DNA, irrespective of the cytosine methylation status. Has reduced affinity for target DNA where the cytosines have been oxidized to 5-hydroxymethylcytosine. Does not bind target DNA where the cytosines have been oxidized to 5-formylcytosine or 5-carboxylcytosine (PubMed:25258363).

Belongs to the EGR C2H2-type zinc-finger protein family.

Research Fields

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Human Diseases > Neurodegenerative diseases > Prion diseases.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

References

1). Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer. BMC Complementary Medicine and Therapies (PubMed: 34049534) [IF=3.9]

Application: WB    Species: Human    Sample: CAL-62 cells

Fig. 1 Effects of artemisinin (ART) on anaplastic thyroid cancer. A CCK-8 proliferation assay after ART treatment for 24 and 48 h. B Flow cytometry of cells treated with or without 100 μM ART for 48 h. C Western blotting of cyclin D1, ANGPTL2, and EGR1 after treatment with 100 μM ART for 48 h. *, statistical significance (p < 0.05); NS, not significant (p > 0.05); error bars, mean ± standard deviation; ratio, the ratio of integrated density (treatment and untreated cells). Gels/blots are cropped for a clear presentation of results. Protein samples derived from the same experiment and gels/blots were processed in parallel. N, groups that did not receive ART treatment. ART, groups that received 100 μM ART treatment. Red, G1/G0; yellow, G2/M; slash, S

Application: WB    Species: human    Sample: CAL-62 cells;BHT-101 cells

Fig. 1| Effects of artemisinin (ART) on anaplastic thyroid cancer.C Western blotting of cyclin D1, ANGPTL2, and EGR1 after treatment with 100 μM ART for 48 h. *, statistical significance (p < 0.05); NS, not significant (p > 0.05); error bars, mean ± standard deviation; ratio, the ratio of integrated density(treatment and untreated cells). Gels/blots are cropped for a clear presentation of results. Protein samples derived from the same experiment and gels/blots were processed in parallel. N, groups that did not receive ART treatment. ART, groups that received 100 μM ART treatment. Red, G1/G0;yellow, G2/M; slash, S
2). The Effect of EGR1 on the Proliferation of Dermal Papilla Cells. Genes (PubMed: 35886025) [IF=3.5]
3). KMT2D Regulates the NCOA6/THRB Signal Axis through Epigenetic Modification to Promote the Migration and Invasion of Papillary Thyroid Cancer. Frontiers in Bioscience - Elite (PubMed: 36722273)

Application: WB    Species: Human    Sample: thyroid papillary carcinoma cells

Fig. 3. The mechanism of KMT2D on papillary thyroid carcinoma cells. (a) ChIP assay. (b) qRT-PCR analysis. (c) Western blotting analysis. A, si-NC; B, si-KMT2D (1); C, si- KMT2D (1).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.